February 15, 2022 -- Bio-Rad Laboratories has launched a range of antidaratumumab antibodies that are specific for daratumumab (Darzalex) and inhibit the binding of the drug to its target, CD38. These highly specific and high-affinity recombinant antibodies are suitable for bioanalysis and drug monitoring of daratumumab and its biosimilars, according to the company.
Daratumumab is an anticancer drug that binds to the CD38 protein overexpressed in multiple myeloma cells, leading to immune-mediated apoptosis of the tumor cell. The new range of antidaratumumab antibodies comprises three fully human immunoglobulin G1 inhibitory antibodies with varying levels of affinity. The antibodies are ideal for use as surrogate positive controls in antidrug antibody assays and for the development of pharmacokinetic bridging enzyme-linked immunosorbent assays to measure the free drug, Bio-Rad said.
Bio-Rad offers a portfolio of recombinant, monoclonal, nonanimal-derived, anti-idiotypic antibodies and drug-target complex binders for the development of highly selective and sensitive assays. These reagents enable researchers to develop robust methods in a short timescale and produce translatable and reproducible results. The antibodies are generated using Human Combinatorial Antibody Libraries and CysDisplay, a proprietary method of phage display, along with guided selection methods to obtain highly targeted reagents.
The antidaratumumab antibodies are approved for in vitro research purposes and for commercial applications providing in vitro testing services to support preclinical and clinical drug development.
Copyright © 2022 scienceboard.net
Member Rewards
Earn points for contributing to market research. Redeem your points for merchandise, travel, or even to help your favorite charity.
Research Topics
Interact with an engaged, global community of your peers who come together to discuss their work and opportunities.
Conferences
Connect
